The application of iPSCs in Parkinson’s disease
Author(s) -
Josefine Jul Jarbæk Nielsen,
Thea P. Lillethorup,
Andreas Nørgaard Glud,
Jens Sörensen,
Dariusz Orłowski
Publication year - 2020
Publication title -
acta neurobiologiae experimentalis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 55
eISSN - 1689-0035
pISSN - 0065-1400
DOI - 10.21307/ane-2020-024
Subject(s) - induced pluripotent stem cell , parkinson's disease , disease , medicine , treatment modality , neuroscience , modalities , bioinformatics , psychology , embryonic stem cell , biology , social science , biochemistry , sociology , gene
The discovery and application of induced pluripotent stem cells (iPSCs) provide a novel treatment modality for diseases, which remain incurable. Particularly, in the treatment of neurodegenerative diseases such as Parkinson's disease (PD), iPSC‑technology holds an interesting prospect for replacement therapy. Currently, the prognostic improvement of PD is limited and relies on symptomatic treatment. However, the symptomatic dopamine‑replacement therapies lose their long‑duration responses, and novel regenerative treatment modalities are needed. Animal models have provided valuable information and identified pathogenic mechanisms underlying PD but the lack of models that recapitulate the complex pathophysiology of the disease postpones further development of novel therapeutics. This review summarizes the possible uses of iPSCs in PD and discusses the future investigations needed for iPSCs as a possible treatment of PD patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom